Skip to main content

Table 1 Clinicopathological characteristics of patients and treatment modalities

From: MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system

Variablesa

 

n (%)

5YRS

PFS, P d

5YRS

OS, P d

(Total = 114)

PFS (SD)

OS (SD)

Age (yr)

≤50

23 (20.2)

0.684 (0.108)

0.072

0.909 (0.043)

0.126

>50

91 (79.8)

0.334 (0.090)

0.698 (0.086)

Age (yr)

≤60

55 (48.2)

0.498 (0.081)

0.585

0.854 (0.065)

0.014

>60

59 (51.8)

0.217 (0.167)

0.569 (0.172)

Sex

M

65 (57.0)

0.452 (0.086)

0.708

0.849 (0.054)

0.156

F

49 (43.0)

0.460 (0.112)

0.452 (0.168)

Initial Symptoms

Headache &vomiting

30 (26.3)

0.609 (0.114)

0.400

0.870 (0.071)

0.266

Seizure

6 (5.3)

0.000 (0.000)

100.0

Neurologic deficit

78 (68.4)

0.387 (0.085)

0.697 (0.085)

ECOG PS

0, 1

73 (65.2)

0.425 (0.086)

0.818

0.789 (0.075)

0.247

2–4

39 (34.8)

0.511 (0.135)

0.752 (0.079)

KPS

≥70

97 (87.4)

0.468 (0.082)

0.001

0.760 (0.065)

0.854

<70

14 (12.6)

0.259 (0.144)

0.821 (0.117)

B Symptoms

Absent

109 (95.6)

0.452 (0.073)

0.284

0.768 (0.061)

0.558

Present

5 (4.4)

0.333 (0.272)

0.800 (0.179)

Serum LDH

Normal

68 (63.6)

0.223 (0.087)

0.005

0.767 (0.102)

0.201

Elevated

39 (36.4)

0.675 (0.102)

0.760 (0.100)

Cell of origin

GCB

24 (21.2)

0.689 (0.120)

0.073

0.795 (0.092)

0.957

Non-GCB

89 (78.8)

0.383 (0.082)

0.756 (0.074)

Involvement of deep structure

Absent

30 (26.3)

0.441 (0.161)

0.219

0.758 (0.129)

0.640

Present

84 (73.7)

0.433 (0.078)

0.762 (0.070)

Extent of disease

Unifocal

42 (36.8)

0.553 (0.119)

0.037

0.753 (0.137)

0.603

Multifocal

72 (63.2)

0.368 (0.088)

0.782 (0.062)

Ocular involvement

Absent

101 (89.4)

0.485 (0.072)

0.985

0.872 (0.046)

0.466

Present

12 (10.6)

0.233 (0.190)

0.525 (0.204)

CSF protein

Normal

39 (42.4)

0.291 (0.142)

0.988

0.675 (0.141)

0.340

Elevated

53 (57.6)

0.467 (0.090)

0.849 (0.058)

CSF cytology

Negative

82 (85.4)

0.356 (0.083)

0.281

0.774 (0.066)

0.693

Positive

14 (14.6)

0.608 (0.158)

0.711 (0.180)

IELSG

0–2

43 (47.3)

0.229 (0.100)

0.093

0.853 (0.101)

0.054

3–5

48 (52.7)

0.638 (0.088)

0.736 (0.074)

Nottingham– Barcelona

0–1

53 (47.3)

0.604 (0.097)

0.001

0.807 (0.080)

0.188

2–3

59 (52.7)

0.264 (0.098)

0.723 (0.084)

MSKCC class

1

21 (18.4)

0.760 (0.106)

0.008

0.847 (0.108)

0.157

2–3

91 (79.8)

0.340 (0.086)

0.688 (0.095)

Radiotherapy

Not done

36 (31.6)

0.586 (0.142)

0.854

0.758 (0.086)

0.057

Done

78 (68.4)

0.416 (0.080)

0.787 (0.068)

Chemotherapy

MVPb

79 (81.4)

0.431 (0.084)

0.519

0.772 (0.072)

0.940

HD-MTX

14 (14.4)

0.442 (0.176)

0.791 (0.138)

Othersc

4 (4.1)

0.750 (0.217)

100.0

Rituximab

Not done

103 (90.4)

0.453 (0.074)

0.756

0.748 (0.067)

0.503

Done

11 (9.6)

0.333 (0.248)

0.909 (0.087)

IT-MTX

Not done

89 (78.1)

0.412 (0.092)

0.649

0.743 (0.076)

0.415

Done

25 (21.9)

0.457 (0.114)

0.832 (0.089)

  1. Abbreviations: ECOG PS The Eastern Cooperative Oncology Group performance score, KPS Karnofsky performance status score, LDH lactate dehydrogenase, GCB germinal center B cell-like, CSF cerebrospinal fluid, IELSG the International Extranodal Lymphoma Study group, MSKCC Memorial Sloan Kettering Cancer Center, MVP combined chemotherapy regimen of high-dose methotrexate, vincristine and procarbazine, HD-MTX high-dose methotrexate, IT-MTX intrathecal methotrexate, PFS progression-free survival, OS overall survival
  2. aSome cases have missing values that lacked the information about the variables
  3. bIncludes 8 patients who received rituximab-MVP
  4. cOthers include COPADM and CHOP
  5. dPFS and OS were analyzed using the Kaplan-Meier method with the log-rank test